Theorem Clinical Research

R&D Trends

NIAID awards SRI International $49M to study new therapies for HIV and AIDS

Monday, July 28, 2014 03:02 PM

SRI International has been awarded a new $49 million, seven-year contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, to conduct preclinical development of potential therapies for HIV infection and AIDS. The contract supports the development of drugs to treat HIV and AIDS and the complications and opportunistic infections associated with the disease, as well as microbicides for preventing sexual transmission of HIV.

More... »


RB to invest $170M to build U.K. R&D center

Monday, July 28, 2014 02:59 PM

RB, a global consumer health and hygiene company formerly called Reckitt Benckiser, will invest $170 millionin its consumer health R&D operations with the creation of a state-of-the-art Center of Scientific Excellence to be based in the U.K.

More... »


Xention awarded $2.4M from Technology Strategy Board for atrial fibrillation medicines

Monday, July 28, 2014 02:56 PM

Xention, a Cambridge-based biopharmaceutical company specializing in the discovery and development of ion channel-modulating drugs, was awarded $2.4 million from the Technology Strategy Board, a U.K. innovation agency, to progress its novel IKAChchannel blockers through preclinical development.

More... »

Shire, ArmaGen ink agreement

Monday, July 28, 2014 02:55 PM

Shire, a global specialty biopharmaceutical company, and ArmaGen, a U.S. privately held biotechnology company, have announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of both the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome (MPS II).

More... »

Bristol-Myers Squibb, Ono Pharmaceutical collaborate in Japan, South Korea, Taiwan

Monday, July 28, 2014 02:54 PM

Bristol-Myers Squibb and Ono Pharmaceutical have signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan.

More... »

Qiagen, AstraZeneca collaborate for lung cancer patients

Monday, July 28, 2014 02:53 PM

Qiagen, a Netherlands-based holding company, has announced a collaboration agreement with AstraZeneca for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with IRESSA, AZ's targeted therapy for non-small cell lung cancer (NSCLC).

More... »

Life expectancy gains threatened as more older Americans suffer from multiple medical conditions

Friday, July 25, 2014 01:01 PM

With nearly four in five older Americans living with multiple chronic medical conditions, a new study by researchers at Johns Hopkins Bloomberg School of Public Health finds the more ailments you have after retirement age, the shorter your life expectancy. The analysis, one of the first to examine the burden of multiple chronic conditions on life expectancy among the elderly, may help explain why increases in life expectancy among older Americans are slowing.

More... »

Foundation awards $1.3 million in research grants to help solve, treat and end Parkinson's disease

Friday, July 25, 2014 12:58 PM

The Parkinson's Disease Foundation (PDF) has announced $1.3 million in funding for more than 30 investigator-initiated research projects to help solve, treat and end Parkinson's disease.  Chosen through a competitive application process, the grants reflect PDF's continued commitment to improving the lives and futures of people touched by Parkinson's. 

More... »

$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research

Friday, July 25, 2014 12:50 PM

The Broad Institute has announced an unprecedented commitment of $650 million from philanthropist Ted Stanley aimed at galvanizing scientific research on psychiatric disorders and bringing new treatments based on molecular understanding to hundreds of millions of people around the world.

More... »

Changes in generic pill color and shape disrupt use

Wednesday, July 23, 2014 10:38 AM

Studying a national cohort of patients who recently suffered a heart attack, researchers from Brigham and Women’s Hospital (BWH) have found variation in appearance of generic drugs is associated with a greater risk of patients stopping their essential post-heart attack drugs.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 2

Roche's $8.3B InterMune buy continues its buying spree with 'bolt-on' deal, fueling record M&A activity

FDA action plan seeks to close gap in women and minority patient representation in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs